CN119325377A - 用阿曲生坦治疗局灶节段性肾小球硬化的方法 - Google Patents

用阿曲生坦治疗局灶节段性肾小球硬化的方法 Download PDF

Info

Publication number
CN119325377A
CN119325377A CN202380039968.2A CN202380039968A CN119325377A CN 119325377 A CN119325377 A CN 119325377A CN 202380039968 A CN202380039968 A CN 202380039968A CN 119325377 A CN119325377 A CN 119325377A
Authority
CN
China
Prior art keywords
subject
atrasentan
weeks
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380039968.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·J·金
V·W·Y·唐
M·卡马戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinook Therapeutics Inc
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Publication of CN119325377A publication Critical patent/CN119325377A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380039968.2A 2022-05-19 2023-05-18 用阿曲生坦治疗局灶节段性肾小球硬化的方法 Pending CN119325377A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263343574P 2022-05-19 2022-05-19
US63/343,574 2022-05-19
PCT/US2023/022681 WO2023225163A1 (en) 2022-05-19 2023-05-18 Methods of treating focal segmental glomerulosclerosis with atrasentan

Publications (1)

Publication Number Publication Date
CN119325377A true CN119325377A (zh) 2025-01-17

Family

ID=88836135

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380039968.2A Pending CN119325377A (zh) 2022-05-19 2023-05-18 用阿曲生坦治疗局灶节段性肾小球硬化的方法

Country Status (10)

Country Link
US (1) US20250352511A1 (enExample)
EP (1) EP4525857A4 (enExample)
JP (1) JP2025517355A (enExample)
KR (1) KR20250013180A (enExample)
CN (1) CN119325377A (enExample)
AU (1) AU2023271840A1 (enExample)
CA (1) CA3252232A1 (enExample)
IL (1) IL316349A (enExample)
MX (1) MX2024013985A (enExample)
WO (1) WO2023225163A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
US20170014386A1 (en) * 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
IL294410B2 (en) * 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
HRP20260121T1 (hr) * 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije

Also Published As

Publication number Publication date
JP2025517355A (ja) 2025-06-05
EP4525857A1 (en) 2025-03-26
AU2023271840A1 (en) 2024-10-31
EP4525857A4 (en) 2026-05-20
KR20250013180A (ko) 2025-01-31
IL316349A (en) 2024-12-01
MX2024013985A (es) 2025-02-10
US20250352511A1 (en) 2025-11-20
CA3252232A1 (en) 2023-11-23
WO2023225163A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
TWI875895B (zh) 用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法
US20230270718A1 (en) Methods of treating diabetic kidney disease
WO2021214023A1 (en) Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
US20220304979A1 (en) Methods of reducing disease flares
US20250352511A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
ES3062063T3 (en) A pharmaceutically acceptable salt of atrasentan for use in a method of treating iga nephropathy
HK40059453A (en) Methods of treating iga nephropathy with atrasentan
HK40094573A (en) Methods of treating iga nephropathy with atrasentan
BR122023026537A2 (pt) Uso de atrasentan para tratar nefropatia por iga

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination